Serotiny, Inc.
High-throughput protein engineering platform enabling design and synthesis of custom protein constructs for research
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2014
- Latest Form D
- $4M, Mar 2023
- Total capital
- $7.1M
- Federal grants
- $150K
- 1 award · 2015
- Rank in peer group#1 of 342
- Private capital raised
- $7M
- 2 Form D · last Mar 2023
- 43 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 4 pending · first 2021
- Rank in peer group#73 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$4M
- Private capital raisedForm D · SEC · 1st filing$3M
- Federal grantNSF · Phase I · SBIR Phase I: Software for High-Throughput Combinatorial Design and Curation of Novel Proteins$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
31months
from Serotiny, Inc.’s first federal award to its first private round.
- First federal award · Dec 2015
- NSF · $150K
- First Form D · Jul 2018
- $3M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 342 peers
Line = medianBiotech · Platform
- Federal grants#1 · top 1%
- Granted patents#73 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Justin FarlowResearcherExecutive Officer, DirectorLinked by 1 patent · $150K in grants as PI
- Colin FarlowExecutive Officer, DirectorNamed in SEC Form D filings
- Eric MoessingerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 5- PendingSynthetic Receptor For Conditional Activation Of Immune CellsUSPTOApplication 18534111
- GrantedMethod And System For Manipulating And Communicating Genetic Constructs Independent Of Their Genetic SequenceUSPTOUS 10,936,746
- PendingSynthetic Receptor For Conditional Activation Of Immune CellsUSPTOApplication PCTUS2022032865
Show all 5 patent records
- Synthetic Receptor For Conditional Activation Of Immune CellsAug 29, 2024 · Application 18534111Pending
- Method And System For Manipulating And Communicating Genetic Constructs Independent Of Their Genetic SequenceMar 2, 2021 · US 10,936,746Granted
- Synthetic Receptor For Conditional Activation Of Immune CellsApplication PCTUS2022032865Pending
- Synthetic Receptor For Conditional Activation Of Immune CellsApplication 63208580Pending
- Method And System For Manipulating And Communicating Genetic Constructs Independent Of Their Genetic SequenceApplication 62437608Pending
Related companies, and why
- Rhino Health Inc.Similar federal contract value in Biotech · null in contracts
- Daedalus Systems Inc./deSimilar federal contract value in Biotech · null in contracts
- Medium CorpSimilar federal contract value in Biotech · null in contracts
- Berkeley Fermentation Science Inc.Similar federal contract value in Biotech · null in contracts
- BACTANA CORP.Similar federal contract value in Biotech · null in contracts
- NOVOME BIOTECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .